拉米夫定联合白细胞介素2治疗慢性乙型肝炎的疗效观察  

Combination of lamivudine and interleukin-2 for chronic hepatits B

作　　者：闫涛[1] 季伟[1] 杜宁[1] 赵鸿[1] 

机构地区：[1]解放军302医院,北京100039

出　　处：《中国现代医学杂志》2005年第7期1056-1058,1061,共4页China Journal of Modern Medicine

摘　　要：目的评价拉米夫定联合白细胞介素2治疗慢性乙型肝炎的疗效和安全性。方法将97例患者随机分为观察组(拉米夫定联合白细胞介素2)和对照组(单用拉米夫定)。拉米夫定疗程至少12个月。观察组联合白细胞介素2,时间为6个月。其中,观察组50例,对照组47例,观察期24个月。结果6个月时,观察组与对照组ALT的复常率分别为82.0%和68.1%(P>0.05);12个月时分别为90.0%和70.2%(P<0.05)。6个月时两组H BeAg阴转率、H BeAg/抗H Be的血清转换率和H BV D N A阴转率差异无显著性(P>0.05);12个月时,两组H BeAg阴转率和H BeA g/抗H Be的血清转换率差异仍无显著性(P>0.05),但观察组H BV D N A阴转率(92.0%)显著高于对照组(70.2%)(P<0.05)。至24个月时,观察组患者血清A LT复常率、H BV D N A阴转率、H BeAg阴转率均显著高于对照组患者(P均<0.05)。用药12个月、24个月时两组H BV Y M D D阳性率相比差异均无显著性(P>0.05)。结论拉米夫定联合白细胞介素2治疗C H B安全有效,优于单用拉米夫定。To evaluate the efficacy and safety of combined lamivudine and interleukin-2 therapy in chronic hepatits B(CHB) patients with positive HBV DNA and HBeAg. Ninety seven patients were randomly divided into combined therapy group and lamivudine alone group. Patients of both groups took lamivudine at least for 1 year. Patients of combined therapy group combined with interleukin-2 in the first 6 months. The total observation period was 24 months. At the end of 6th month, the normalization rate of ALT were 82.0% in the combined therapy group and 68.1% in the lamivudine alone group (P>0.05); The negativation rate of serum HBV DNA and HBeAg/anti HBe seroconversion rate in both groups showed no significant difference(P>0.05). At the end of 12th month, the normalization rate of ALT and negativation rate of serum HBV DNA in two groups showed significant difference(P<0.05), while negativation rate of HBeAg and HBeAg /anti HBe seroconversion rate and HBV DNA YMDD positive rate were not (P>0.05). At the end of 24th month, the combined therapy group showed higher normalization rate of ALT and negativation rate of serum HBV DNA and HBeAg(P<0.05). [Conclusions] The combination therapy of lamivudine and interleukin-2 is effective and safe in CHB patients.

关 键 词：慢性乙型肝炎 拉米夫定 白细胞介素2 联合治疗 

分 类 号：R512.62[医药卫生—内科学]